Latest Research, Industry, Medical and Scientific News
Significantly lower levels of oestrogen in peri-menopausal and post-menopausal women could increase their risk of stress urinary incontinence, according to Austrian researchers. They noted that sex steroid levels changed markedly during menopause, and oestrogen deficiency after menopause caused changes within the urogenital tract. Their study included 47 women with stress urinary incontinence who were matched with 47 controls. The findings suggested that low levels of circulating sex steroids might have a negative impact on the function of the lower urinary tract and on mechanisms involved with continence. Read more.
Nursing Times, June 8, 2017
Urinary incontinence in women is common, with almost 50% of adult women experiencing leakage at least occasionally. Genetic or heritable factors are known to contribute to half of all cases, but until now studies had failed to identify the genetic variants associated with the condition. Speaking at the annual conference of the European Society of Human Genetics today (Monday), Dr Rufus Cartwright, MD, a visiting researcher in the Department of Epidemiology and Biostatistics, Imperial College, London, UK, will say that his team’s investigations hold out the promise that drugs already used for the treatment of other conditions can help affected women combat this distressing problem. Read more.
Source: Medical Xpress, May 29, 2017
A possible link between low levels of testosterone in women and urinary incontinence raises the possibility that testosterone replacement therapy might help, results from a new study suggest. “Testosterone may prevent pelvic floor atrophy, thereby reducing the risk of urinary incontinence,” said investigator Michelle Kim, MD, PhD, from Massachusetts General Hospital in Boston. Levator ani muscles are known to have androgen receptors. In one rodent model, testosterone administered after surgically induced urinary incontinence resulted in levator hypertrophy (Int Urol Nephrol. 2011;43:1003-1008). Because it is unclear whether the same association exists in humans, Dr Kim and her colleagues were prompted to assess the correlation between testosterone and incontinence. Read more.
Source: Medscape, May 18, 2017
Acupuncture outperforms drug therapy for the treatment of mild to moderate female stress urinary incontinence (FSUI). Researchers from Weihai City Hospital of Traditional Chinese Medicine conclude that electroacupuncture is effective for the control of FSUI. In the study, an electroacupuncture treatment group produced a positive patient outcome rate of 86.7%. The drug control group produced a 68.9% positive patient outcome rate for the treatment of FSUI. The electroacupuncture group had a significantly higher complete recovery rate and total effective rate. Read more.
Source: Health CMi, May 9, 2017
In order to help normalize the topic of bladder leaks, Always Discreet is working with retailers to educate women nationwide. As an example, Procter & Gamble’s Always Discreet brand on Thursday worked with Walmart to launch a new, inspirational video to help women understand how common bladder leaks are and to rethink their negative feelings. “Because many women avoid talking about their bladder leaks, they can often feel alone in their experience, embarrassed to bring up the topic, and hesitant to shop for and wear incontinence products,” stated Barbara Hannah Grufferman, positive living expert, author and Always Discreet spokesperson. “Over the years, I’ve spoken to thousands of women around the country who have bladder leaks, and most women don’t realize how common and normal it is. The good news is that once women realize how many other women experience it too, they feel better about it and themselves,” she said. “That’s what’s been captured in this video, and the hope is that women watch it, make that connection for themselves and feel more confident, empowered and compelled to live their best lives and stand in solidarity with the many other women who experience bladder leaks too.” Read more.
Source: Drug Store News, May 4, 2017
Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a study. While patients reported a decline in these quality of life measures immediately after brachytherapy, they achieved a full recovery within six months. Brachytherapy involves inserting radioactive seeds in or near tumor to kill it. The research, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was published in the Journal of Radiation Oncology, Biology, Physics. “This study reinforces the position of Cesium 131 as an effective, patient-friendly treatment for localized prostate cancer,” Bill Cavanagh, chief scientific officer of the brachytherapy company IsoRay, said in a news release. “This is especially important as multiple studies are emerging that strongly suggest that the inclusion of brachytherapy must be considered for the treatment of high-risk prostate cancer – the toughest localized prostate cancer to cure.” Read more.
Source: Prostate Cancer News Today, May 4, 2017